The global market for Attenuated Vaccine was valued at US$ 5486 million in the year 2024 and is projected to reach a revised size of US$ 8310 million by 2031, growing at a CAGR of 6.2% during the forecast period.

Attenuated Vaccine Market

The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.

Report Scope

This report aims to provide a comprehensive presentation of the global market for Attenuated Vaccine, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Attenuated Vaccine.

The Attenuated Vaccine market size, estimations, and forecasts are provided in terms of sales volume (K Doses) and revenue ($ millions), considering 2024 as the base year, with history and forecast data for the period from 2020 to 2031. This report segments the global Attenuated Vaccine market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.

For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.

The report will help the Attenuated Vaccine manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.

Scope of Attenuated Vaccine Market Report

Report Metric	Details
Report Name	Attenuated Vaccine Market
Accounted market size in year	US$ 5486 million
Forecasted market size in 2031	US$ 8310 million
CAGR	6.2%
Base Year	year
Forecasted years	2025 - 2031
Segment by Type	Bacterial Vaccine Viral Vaccine
Segment by Application	Hospital Clinic Others
Consumption by Region	North America (United States, Canada) Europe (Germany, France, UK, Italy, Russia) Asia-Pacific (China, Japan, South Korea, Taiwan) Southeast Asia (India) Latin America (Mexico, Brazil)
By Company	Merck & Co., GlaxoSmithKline plc, Pfizer Inc, Sanofi, Astellas Pharma, Johnson & Johnson, CSL Limited, Serum Institute of India Pvt. Ltd., Biken, Green Cross Corporation, Shanghai Rongsheng Biotech, Changchun BCHT Biotechnology Co.,Ltd
Forecast units	USD million in value
Report coverage	Revenue and volume forecast, company share, competitive landscape, growth factors and trends

Core Chapters

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Attenuated Vaccine manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Attenuated Vaccine in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.

FAQ for this report

How fast is Attenuated Vaccine Market growing?

Ans: The Attenuated Vaccine Market witnessing a CAGR of 6.2% during the forecast period 2025-2031.

What is the Attenuated Vaccine Market size in 2031?

Ans: The Attenuated Vaccine Market size in 2031 will be US$ 8310 million.

Who are the main players in the Attenuated Vaccine Market report?

Ans: The main players in the Attenuated Vaccine Market are Merck & Co., GlaxoSmithKline plc, Pfizer Inc, Sanofi, Astellas Pharma, Johnson & Johnson, CSL Limited, Serum Institute of India Pvt. Ltd., Biken, Green Cross Corporation, Shanghai Rongsheng Biotech, Changchun BCHT Biotechnology Co.,Ltd

What are the Application segmentation covered in the Attenuated Vaccine Market report?

Ans: The Applications covered in the Attenuated Vaccine Market report are Hospital, Clinic, Others

What are the Type segmentation covered in the Attenuated Vaccine Market report?

Ans: The Types covered in the Attenuated Vaccine Market report are Bacterial Vaccine, Viral Vaccine

1 Attenuated Vaccine Market Overview

1.1 Product Definition

1.2 Attenuated Vaccine by Type

1.2.1 Global Attenuated Vaccine Market Value Comparison by Type (2024 VS 2031)

1.2.2 Bacterial Vaccine

1.2.3 Viral Vaccine

1.3 Attenuated Vaccine by Application

1.3.1 Global Attenuated Vaccine Market Value by Application (2024 VS 2031)

1.3.2 Hospital

1.3.3 Clinic

1.3.4 Others

1.4 Global Attenuated Vaccine Market Size Estimates and Forecasts

1.4.1 Global Attenuated Vaccine Revenue 2020-2031

1.4.2 Global Attenuated Vaccine Sales 2020-2031

1.4.3 Global Attenuated Vaccine Market Average Price (2020-2031)

1.5 Assumptions and Limitations

2 Attenuated Vaccine Market Competition by Manufacturers

2.1 Global Attenuated Vaccine Sales Market Share by Manufacturers (2020-2025)

2.2 Global Attenuated Vaccine Revenue Market Share by Manufacturers (2020-2025)

2.3 Global Attenuated Vaccine Average Price by Manufacturers (2020-2025)

2.4 Global Key Players of Attenuated Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

2.5 Global Key Manufacturers of Attenuated Vaccine, Manufacturing Sites & Headquarters

2.6 Global Key Manufacturers of Attenuated Vaccine, Product Type & Application

2.7 Global Key Manufacturers of Attenuated Vaccine, Date of Enter into This Industry

2.8 Global Attenuated Vaccine Market Competitive Situation and Trends

2.8.1 Global Attenuated Vaccine Market Concentration Rate

2.8.2 The Global 5 and 10 Largest Attenuated Vaccine Players Market Share by Revenue

2.8.3 Global Attenuated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3 Global Attenuated Vaccine Market Scenario by Region

3.1 Global Attenuated Vaccine Market Size by Region: 2020 Versus 2024 Versus 2031

3.2 Global Attenuated Vaccine Sales by Region: 2020-2031

3.2.1 Global Attenuated Vaccine Sales by Region: 2020-2025

3.2.2 Global Attenuated Vaccine Sales by Region: 2026-2031

3.3 Global Attenuated Vaccine Revenue by Region: 2020-2031

3.3.1 Global Attenuated Vaccine Revenue by Region: 2020-2025

3.3.2 Global Attenuated Vaccine Revenue by Region: 2026-2031

3.4 North America Attenuated Vaccine Market Facts & Figures by Country

3.4.1 North America Attenuated Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.4.2 North America Attenuated Vaccine Sales by Country (2020-2031)

3.4.3 North America Attenuated Vaccine Revenue by Country (2020-2031)

3.4.4 United States

3.4.5 Canada

3.5 Europe Attenuated Vaccine Market Facts & Figures by Country

3.5.1 Europe Attenuated Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.5.2 Europe Attenuated Vaccine Sales by Country (2020-2031)

3.5.3 Europe Attenuated Vaccine Revenue by Country (2020-2031)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific Attenuated Vaccine Market Facts & Figures by Region

3.6.1 Asia Pacific Attenuated Vaccine Market Size by Region: 2020 VS 2024 VS 2031

3.6.2 Asia Pacific Attenuated Vaccine Sales by Region (2020-2031)

3.6.3 Asia Pacific Attenuated Vaccine Revenue by Region (2020-2031)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Indonesia

3.6.11 Thailand

3.6.12 Malaysia

3.7 Latin America Attenuated Vaccine Market Facts & Figures by Country

3.7.1 Latin America Attenuated Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.7.2 Latin America Attenuated Vaccine Sales by Country (2020-2031)

3.7.3 Latin America Attenuated Vaccine Revenue by Country (2020-2031)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa Attenuated Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa Attenuated Vaccine Market Size by Country: 2020 VS 2024 VS 2031

3.8.2 Middle East and Africa Attenuated Vaccine Sales by Country (2020-2031)

3.8.3 Middle East and Africa Attenuated Vaccine Revenue by Country (2020-2031)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4 Segment by Type

4.1 Global Attenuated Vaccine Sales by Type (2020-2031)

4.1.1 Global Attenuated Vaccine Sales by Type (2020-2025)

4.1.2 Global Attenuated Vaccine Sales by Type (2026-2031)

4.1.3 Global Attenuated Vaccine Sales Market Share by Type (2020-2031)

4.2 Global Attenuated Vaccine Revenue by Type (2020-2031)

4.2.1 Global Attenuated Vaccine Revenue by Type (2020-2025)

4.2.2 Global Attenuated Vaccine Revenue by Type (2026-2031)

4.2.3 Global Attenuated Vaccine Revenue Market Share by Type (2020-2031)

4.3 Global Attenuated Vaccine Price by Type (2020-2031)

5 Segment by Application

5.1 Global Attenuated Vaccine Sales by Application (2020-2031)

5.1.1 Global Attenuated Vaccine Sales by Application (2020-2025)

5.1.2 Global Attenuated Vaccine Sales by Application (2026-2031)

5.1.3 Global Attenuated Vaccine Sales Market Share by Application (2020-2031)

5.2 Global Attenuated Vaccine Revenue by Application (2020-2031)

5.2.1 Global Attenuated Vaccine Revenue by Application (2020-2025)

5.2.2 Global Attenuated Vaccine Revenue by Application (2026-2031)

5.2.3 Global Attenuated Vaccine Revenue Market Share by Application (2020-2031)

5.3 Global Attenuated Vaccine Price by Application (2020-2031)

6 Key Companies Profiled

6.1 Merck & Co.

6.1.1 Merck & Co. Company Information

6.1.2 Merck & Co. Description and Business Overview

6.1.3 Merck & Co. Attenuated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.1.4 Merck & Co. Attenuated Vaccine Product Portfolio

6.1.5 Merck & Co. Recent Developments/Updates

6.2 GlaxoSmithKline plc

6.2.1 GlaxoSmithKline plc Company Information

6.2.2 GlaxoSmithKline plc Description and Business Overview

6.2.3 GlaxoSmithKline plc Attenuated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.2.4 GlaxoSmithKline plc Attenuated Vaccine Product Portfolio

6.2.5 GlaxoSmithKline plc Recent Developments/Updates

6.3 Pfizer Inc

6.3.1 Pfizer Inc Company Information

6.3.2 Pfizer Inc Description and Business Overview

6.3.3 Pfizer Inc Attenuated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.3.4 Pfizer Inc Attenuated Vaccine Product Portfolio

6.3.5 Pfizer Inc Recent Developments/Updates

6.4 Sanofi

6.4.1 Sanofi Company Information

6.4.2 Sanofi Description and Business Overview

6.4.3 Sanofi Attenuated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.4.4 Sanofi Attenuated Vaccine Product Portfolio

6.4.5 Sanofi Recent Developments/Updates

6.5 Astellas Pharma

6.5.1 Astellas Pharma Company Information

6.5.2 Astellas Pharma Description and Business Overview

6.5.3 Astellas Pharma Attenuated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.5.4 Astellas Pharma Attenuated Vaccine Product Portfolio

6.5.5 Astellas Pharma Recent Developments/Updates

6.6 Johnson & Johnson

6.6.1 Johnson & Johnson Company Information

6.6.2 Johnson & Johnson Description and Business Overview

6.6.3 Johnson & Johnson Attenuated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.6.4 Johnson & Johnson Attenuated Vaccine Product Portfolio

6.6.5 Johnson & Johnson Recent Developments/Updates

6.7 CSL Limited

6.7.1 CSL Limited Company Information

6.7.2 CSL Limited Description and Business Overview

6.7.3 CSL Limited Attenuated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.7.4 CSL Limited Attenuated Vaccine Product Portfolio

6.7.5 CSL Limited Recent Developments/Updates

6.8 Serum Institute of India Pvt. Ltd.

6.8.1 Serum Institute of India Pvt. Ltd. Company Information

6.8.2 Serum Institute of India Pvt. Ltd. Description and Business Overview

6.8.3 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.8.4 Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product Portfolio

6.8.5 Serum Institute of India Pvt. Ltd. Recent Developments/Updates

6.9 Biken

6.9.1 Biken Company Information

6.9.2 Biken Description and Business Overview

6.9.3 Biken Attenuated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.9.4 Biken Attenuated Vaccine Product Portfolio

6.9.5 Biken Recent Developments/Updates

6.10 Green Cross Corporation

6.10.1 Green Cross Corporation Company Information

6.10.2 Green Cross Corporation Description and Business Overview

6.10.3 Green Cross Corporation Attenuated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.10.4 Green Cross Corporation Attenuated Vaccine Product Portfolio

6.10.5 Green Cross Corporation Recent Developments/Updates

6.11 Shanghai Rongsheng Biotech

6.11.1 Shanghai Rongsheng Biotech Company Information

6.11.2 Shanghai Rongsheng Biotech Description and Business Overview

6.11.3 Shanghai Rongsheng Biotech Attenuated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.11.4 Shanghai Rongsheng Biotech Attenuated Vaccine Product Portfolio

6.11.5 Shanghai Rongsheng Biotech Recent Developments/Updates

6.12 Changchun BCHT Biotechnology Co.,Ltd

6.12.1 Changchun BCHT Biotechnology Co.,Ltd Company Information

6.12.2 Changchun BCHT Biotechnology Co.,Ltd Description and Business Overview

6.12.3 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales, Revenue and Gross Margin (2020-2025)

6.12.4 Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product Portfolio

6.12.5 Changchun BCHT Biotechnology Co.,Ltd Recent Developments/Updates

7 Industry Chain and Sales Channels Analysis

7.1 Attenuated Vaccine Industry Chain Analysis

7.2 Attenuated Vaccine Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 Attenuated Vaccine Production Mode & Process Analysis

7.4 Attenuated Vaccine Sales and Marketing

7.4.1 Attenuated Vaccine Sales Channels

7.4.2 Attenuated Vaccine Distributors

7.5 Attenuated Vaccine Customer Analysis

8 Attenuated Vaccine Market Dynamics

8.1 Attenuated Vaccine Industry Trends

8.2 Attenuated Vaccine Market Drivers

8.3 Attenuated Vaccine Market Challenges

8.4 Attenuated Vaccine Market Restraints

9 Research Findings and Conclusion

10 Methodology and Data Source

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

FEATURED COMPANIES

Green Cross Corporation

Shanghai Rongsheng Biotech

Changchun BCHT Biotechnology Co.,Ltd

Serum Institute of India Pvt. Ltd

List of Tables

Table 1. Global Attenuated Vaccine Market Value Comparison by Type (2024 VS 2031) & (US$ Million)

Table 2. Global Attenuated Vaccine Market Value by Application (2024 VS 2031) & (US$ Million)

Table 3. Global Attenuated Vaccine Market Competitive Situation by Manufacturers in 2024

Table 4. Global Attenuated Vaccine Sales (K Doses) of Key Manufacturers (2020-2025)

Table 5. Global Attenuated Vaccine Sales Market Share by Manufacturers (2020-2025)

Table 6. Global Attenuated Vaccine Revenue (US$ Million) by Manufacturers (2020-2025)

Table 7. Global Attenuated Vaccine Revenue Share by Manufacturers (2020-2025)

Table 8. Global Market Attenuated Vaccine Average Price (US$/Dose) of Key Manufacturers (2020-2025)

Table 9. Global Key Players of Attenuated Vaccine, Industry Ranking, 2022 VS 2023 VS 2024

Table 10. Global Key Manufacturers of Attenuated Vaccine, Manufacturing Sites & Headquarters

Table 11. Global Key Manufacturers of Attenuated Vaccine, Product Type & Application

Table 12. Global Key Manufacturers of Attenuated Vaccine, Date of Enter into This Industry

Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

Table 14. Global Attenuated Vaccine by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Attenuated Vaccine as of 2024)

Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

Table 16. Global Attenuated Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Table 17. Global Attenuated Vaccine Sales by Region (2020-2025) & (K Doses)

Table 18. Global Attenuated Vaccine Sales Market Share by Region (2020-2025)

Table 19. Global Attenuated Vaccine Sales by Region (2026-2031) & (K Doses)

Table 20. Global Attenuated Vaccine Sales Market Share by Region (2026-2031)

Table 21. Global Attenuated Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 22. Global Attenuated Vaccine Revenue Market Share by Region (2020-2025)

Table 23. Global Attenuated Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 24. Global Attenuated Vaccine Revenue Market Share by Region (2026-2031)

Table 25. North America Attenuated Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 26. North America Attenuated Vaccine Sales by Country (2020-2025) & (K Doses)

Table 27. North America Attenuated Vaccine Sales by Country (2026-2031) & (K Doses)

Table 28. North America Attenuated Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 29. North America Attenuated Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 30. Europe Attenuated Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 31. Europe Attenuated Vaccine Sales by Country (2020-2025) & (K Doses)

Table 32. Europe Attenuated Vaccine Sales by Country (2026-2031) & (K Doses)

Table 33. Europe Attenuated Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 34. Europe Attenuated Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 35. Asia Pacific Attenuated Vaccine Revenue by Region: 2020 VS 2024 VS 2031 (US$ Million)

Table 36. Asia Pacific Attenuated Vaccine Sales by Region (2020-2025) & (K Doses)

Table 37. Asia Pacific Attenuated Vaccine Sales by Region (2026-2031) & (K Doses)

Table 38. Asia Pacific Attenuated Vaccine Revenue by Region (2020-2025) & (US$ Million)

Table 39. Asia Pacific Attenuated Vaccine Revenue by Region (2026-2031) & (US$ Million)

Table 40. Latin America Attenuated Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 41. Latin America Attenuated Vaccine Sales by Country (2020-2025) & (K Doses)

Table 42. Latin America Attenuated Vaccine Sales by Country (2026-2031) & (K Doses)

Table 43. Latin America Attenuated Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 44. Latin America Attenuated Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 45. Middle East and Africa Attenuated Vaccine Revenue by Country: 2020 VS 2024 VS 2031 (US$ Million)

Table 46. Middle East and Africa Attenuated Vaccine Sales by Country (2020-2025) & (K Doses)

Table 47. Middle East and Africa Attenuated Vaccine Sales by Country (2026-2031) & (K Doses)

Table 48. Middle East and Africa Attenuated Vaccine Revenue by Country (2020-2025) & (US$ Million)

Table 49. Middle East and Africa Attenuated Vaccine Revenue by Country (2026-2031) & (US$ Million)

Table 50. Global Attenuated Vaccine Sales (K Doses) by Type (2020-2025)

Table 51. Global Attenuated Vaccine Sales (K Doses) by Type (2026-2031)

Table 52. Global Attenuated Vaccine Sales Market Share by Type (2020-2025)

Table 53. Global Attenuated Vaccine Sales Market Share by Type (2026-2031)

Table 54. Global Attenuated Vaccine Revenue (US$ Million) by Type (2020-2025)

Table 55. Global Attenuated Vaccine Revenue (US$ Million) by Type (2026-2031)

Table 56. Global Attenuated Vaccine Revenue Market Share by Type (2020-2025)

Table 57. Global Attenuated Vaccine Revenue Market Share by Type (2026-2031)

Table 58. Global Attenuated Vaccine Price (US$/Dose) by Type (2020-2025)

Table 59. Global Attenuated Vaccine Price (US$/Dose) by Type (2026-2031)

Table 60. Global Attenuated Vaccine Sales (K Doses) by Application (2020-2025)

Table 61. Global Attenuated Vaccine Sales (K Doses) by Application (2026-2031)

Table 62. Global Attenuated Vaccine Sales Market Share by Application (2020-2025)

Table 63. Global Attenuated Vaccine Sales Market Share by Application (2026-2031)

Table 64. Global Attenuated Vaccine Revenue (US$ Million) by Application (2020-2025)

Table 65. Global Attenuated Vaccine Revenue (US$ Million) by Application (2026-2031)

Table 66. Global Attenuated Vaccine Revenue Market Share by Application (2020-2025)

Table 67. Global Attenuated Vaccine Revenue Market Share by Application (2026-2031)

Table 68. Global Attenuated Vaccine Price (US$/Dose) by Application (2020-2025)

Table 69. Global Attenuated Vaccine Price (US$/Dose) by Application (2026-2031)

Table 70. Merck & Co. Company Information

Table 71. Merck & Co. Description and Business Overview

Table 72. Merck & Co. Attenuated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 73. Merck & Co. Attenuated Vaccine Product

Table 74. Merck & Co. Recent Developments/Updates

Table 75. GlaxoSmithKline plc Company Information

Table 76. GlaxoSmithKline plc Description and Business Overview

Table 77. GlaxoSmithKline plc Attenuated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 78. GlaxoSmithKline plc Attenuated Vaccine Product

Table 79. GlaxoSmithKline plc Recent Developments/Updates

Table 80. Pfizer Inc Company Information

Table 81. Pfizer Inc Description and Business Overview

Table 82. Pfizer Inc Attenuated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 83. Pfizer Inc Attenuated Vaccine Product

Table 84. Pfizer Inc Recent Developments/Updates

Table 85. Sanofi Company Information

Table 86. Sanofi Description and Business Overview

Table 87. Sanofi Attenuated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 88. Sanofi Attenuated Vaccine Product

Table 89. Sanofi Recent Developments/Updates

Table 90. Astellas Pharma Company Information

Table 91. Astellas Pharma Description and Business Overview

Table 92. Astellas Pharma Attenuated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 93. Astellas Pharma Attenuated Vaccine Product

Table 94. Astellas Pharma Recent Developments/Updates

Table 95. Johnson & Johnson Company Information

Table 96. Johnson & Johnson Description and Business Overview

Table 97. Johnson & Johnson Attenuated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 98. Johnson & Johnson Attenuated Vaccine Product

Table 99. Johnson & Johnson Recent Developments/Updates

Table 100. CSL Limited Company Information

Table 101. CSL Limited Description and Business Overview

Table 102. CSL Limited Attenuated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 103. CSL Limited Attenuated Vaccine Product

Table 104. CSL Limited Recent Developments/Updates

Table 105. Serum Institute of India Pvt. Ltd. Company Information

Table 106. Serum Institute of India Pvt. Ltd. Description and Business Overview

Table 107. Serum Institute of India Pvt. Ltd. Attenuated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 108. Serum Institute of India Pvt. Ltd. Attenuated Vaccine Product

Table 109. Serum Institute of India Pvt. Ltd. Recent Developments/Updates

Table 110. Biken Company Information

Table 111. Biken Description and Business Overview

Table 112. Biken Attenuated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 113. Biken Attenuated Vaccine Product

Table 114. Biken Recent Developments/Updates

Table 115. Green Cross Corporation Company Information

Table 116. Green Cross Corporation Description and Business Overview

Table 117. Green Cross Corporation Attenuated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 118. Green Cross Corporation Attenuated Vaccine Product

Table 119. Green Cross Corporation Recent Developments/Updates

Table 120. Shanghai Rongsheng Biotech Company Information

Table 121. Shanghai Rongsheng Biotech Description and Business Overview

Table 122. Shanghai Rongsheng Biotech Attenuated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 123. Shanghai Rongsheng Biotech Attenuated Vaccine Product

Table 124. Shanghai Rongsheng Biotech Recent Developments/Updates

Table 125. Changchun BCHT Biotechnology Co.,Ltd Company Information

Table 126. Changchun BCHT Biotechnology Co.,Ltd Description and Business Overview

Table 127. Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Sales (K Doses), Revenue (US$ Million), Price (US$/Dose) and Gross Margin (2020-2025)

Table 128. Changchun BCHT Biotechnology Co.,Ltd Attenuated Vaccine Product

Table 129. Changchun BCHT Biotechnology Co.,Ltd Recent Developments/Updates

Table 130. Key Raw Materials Lists

Table 131. Raw Materials Key Suppliers Lists

Table 132. Attenuated Vaccine Distributors List

Table 133. Attenuated Vaccine Customers List

Table 134. Attenuated Vaccine Market Trends

Table 135. Attenuated Vaccine Market Drivers

Table 136. Attenuated Vaccine Market Challenges

Table 137. Attenuated Vaccine Market Restraints

Table 138. Research Programs/Design for This Report

Table 139. Key Data Information from Secondary Sources

Table 140. Key Data Information from Primary Sources

Table 141. Authors List of This Report

List of Figures

Figure 1. Product Picture of Attenuated Vaccine

Figure 2. Global Attenuated Vaccine Market Value Comparison by Type (2020-2031) & (US$ Million)

Figure 3. Global Attenuated Vaccine Market Share by Type: 2024 & 2031

Figure 4. Bacterial Vaccine Product Picture

Figure 5. Viral Vaccine Product Picture

Figure 6. Global Attenuated Vaccine Market Value by Application (2020-2031) & (US$ Million)

Figure 7. Global Attenuated Vaccine Market Share by Application: 2024 & 2031

Figure 8. Hospital

Figure 9. Clinic

Figure 10. Others

Figure 11. Global Attenuated Vaccine Revenue, (US$ Million), 2020 VS 2024 VS 2031

Figure 12. Global Attenuated Vaccine Market Size (2020-2031) & (US$ Million)

Figure 13. Global Attenuated Vaccine Sales (2020-2031) & (K Doses)

Figure 14. Global Attenuated Vaccine Average Price (US$/Dose) & (2020-2031)

Figure 15. Attenuated Vaccine Report Years Considered

Figure 16. Attenuated Vaccine Sales Share by Manufacturers in 2024

Figure 17. Global Attenuated Vaccine Revenue Share by Manufacturers in 2024

Figure 18. Global 5 and 10 Largest Attenuated Vaccine Players: Market Share by Revenue in Attenuated Vaccine in 2024

Figure 19. Attenuated Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2020 VS 2024

Figure 20. Global Attenuated Vaccine Market Size by Region (US$ Million): 2020 VS 2024 VS 2031

Figure 21. North America Attenuated Vaccine Sales Market Share by Country (2020-2031)

Figure 22. North America Attenuated Vaccine Revenue Market Share by Country (2020-2031)

Figure 23. United States Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 24. Canada Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 25. Europe Attenuated Vaccine Sales Market Share by Country (2020-2031)

Figure 26. Europe Attenuated Vaccine Revenue Market Share by Country (2020-2031)

Figure 27. Germany Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 28. France Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 29. U.K. Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 30. Italy Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 31. Russia Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 32. Asia Pacific Attenuated Vaccine Sales Market Share by Region (2020-2031)

Figure 33. Asia Pacific Attenuated Vaccine Revenue Market Share by Region (2020-2031)

Figure 34. China Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 35. Japan Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 36. South Korea Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 37. India Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 38. Australia Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 39. China Taiwan Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 40. Indonesia Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 41. Thailand Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 42. Malaysia Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 43. Latin America Attenuated Vaccine Sales Market Share by Country (2020-2031)

Figure 44. Latin America Attenuated Vaccine Revenue Market Share by Country (2020-2031)

Figure 45. Mexico Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 46. Brazil Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 47. Argentina Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 48. Middle East and Africa Attenuated Vaccine Sales Market Share by Country (2020-2031)

Figure 49. Middle East and Africa Attenuated Vaccine Revenue Market Share by Country (2020-2031)

Figure 50. Turkey Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 51. Saudi Arabia Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 52. UAE Attenuated Vaccine Revenue Growth Rate (2020-2031) & (US$ Million)

Figure 53. Global Sales Market Share of Attenuated Vaccine by Type (2020-2031)

Figure 54. Global Revenue Market Share of Attenuated Vaccine by Type (2020-2031)

Figure 55. Global Attenuated Vaccine Price (US$/Dose) by Type (2020-2031)

Figure 56. Global Sales Market Share of Attenuated Vaccine by Application (2020-2031)

Figure 57. Global Revenue Market Share of Attenuated Vaccine by Application (2020-2031)

Figure 58. Global Attenuated Vaccine Price (US$/Dose) by Application (2020-2031)

Figure 59. Attenuated Vaccine Value Chain

Figure 60. Channels of Distribution (Direct Vs Distribution)

Figure 61. Bottom-up and Top-down Approaches for This Report

Figure 62. Data Triangulation

Figure 63. Key Executives Interviewed

SELECT A FORMAT

Added to Cart

Single User

Electronic (PDF)

$2900

This license allows only one user to access the PDF.

Multi User

Electronic (PDF)

$4350

This license allows 1 - 5 user to access the PDF, license is suitable for small groups of 5 users working together

Enterprise User

Electronic (PDF)

$5800

This license allows users/teams in a same Enterprise to use this report, various departments within an enterpise can use this report

Add to Cart

Buy Now (15% Discount)

HAVE A QUERY?

INQUIRE ABOUT REPORT EMAIL US

OUR CUSTOMER

SIMILAR REPORTS

aluates Reports

Support Contacts

U.S. (TOLL FREE)

+1 (425) 388-2538

sales@valuates.com

THE COMPANY

OUR PRODUCTS

CUSTOMER SUPPORT

CONTACT
FAQ

POLICES

THE COMPANY

ABOUT US

CUSTOMER SUPPORT

CONTACT
FAQ

OUR PRODUCTS

POLICES

Sitemap - Privacy Policy - Terms & Conditions

Global Attenuated Vaccine Market Research Report 2025

Published Date: March 2025

Report Code: QYRE-Auto-11N15105

Global Attenuated Vaccine Market Research Report 2025

FEATURED COMPANIES

Attenuated Vaccine Market Size

Attenuated Vaccine Market

Report Scope

Scope of Attenuated Vaccine Market Report

Core Chapters

FAQ for this report

How fast is Attenuated Vaccine Market growing?

What is the Attenuated Vaccine Market size in 2031?

Who are the main players in the Attenuated Vaccine Market report?

What are the Application segmentation covered in the Attenuated Vaccine Market report?

What are the Type segmentation covered in the Attenuated Vaccine Market report?

FEATURED COMPANIES

Global Silicon Oxide Precursor Market Research Report 2023

Single User, Electronic (PDF)